Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
31M
-
Shares change
-
+175K
-
Total reported value, excl. options
-
$101M
-
Value change
-
+$962K
-
Put/Call ratio
-
23.75
-
Number of buys
-
19
-
Number of sells
-
-28
-
Price
-
$3.25
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q1 2017
62 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q1 2017.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31M shares
of 193M outstanding shares and own 16.04% of the company stock.
Largest 10 shareholders include QVT Financial LP (16M shares), PRIMECAP MANAGEMENT CO/CA/ (3.94M shares), D. E. Shaw & Co., Inc. (1.75M shares), ARMISTICE CAPITAL, LLC (1.6M shares), RTW INVESTMENTS, LP (1.45M shares), Falcon Edge Capital LP (1.12M shares), BANK OF MONTREAL /CAN/ (858K shares), AXA (809K shares), SABBY MANAGEMENT, LLC (648K shares), and K2 PRINCIPAL FUND, L.P. (428K shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.